PD-L1/PD-1 Axis in Glioblastoma Multiforme

Area of Science:

• Neuro-oncology
• Immunology
• Cancer Biology

Background:

• Glioblastoma (GBM) is an aggressive primary brain cancer with a median survival of 14-17 months.
• The programmed cell death-1 (PD-1) and programmed cell death ligand (PD-L1) pathway plays a crucial role in GBM invasion and immune evasion.
• PD-L1 expression on GBM cells can suppress T cell responses by activating PD-1 receptors on microglia.

Purpose of the Study:

• To investigate the role of the PD-1/PD-L1 axis in glioblastoma multiforme (GBM) pathogenesis.
• To evaluate the therapeutic potential of targeting the PD-1/PD-L1 pathway in preclinical GBM models.

Main Methods:

• Analysis of PD-1/PD-L1 interactions in GBM.
• Assessment of PD-L1 expression as a potential tumor biomarker.
• Evaluation of monoclonal antibodies targeting the PD-1/PD-L1 axis in preclinical GBM mouse models.

Main Results:

• The PD-1/PD-L1 axis promotes GBM invasion and immune suppression.
• PD-L1 expression correlates with glioma WHO grading.
• Monoclonal antibodies targeting PD-1/PD-L1 demonstrated safety and efficacy in preclinical GBM models, leading to tumor regression and prolonged survival.

Conclusions:

• Targeting the PD-1/PD-L1 pathway represents a promising therapeutic strategy for GBM.
• Further clinical trials are warranted to assess the efficacy of PD-1/PD-L1 inhibitors in patients with recurrent glioblastoma.